Literature DB >> 22871916

The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T ¹H-MRS study.

Kejia Cai1, Ravi Pr Nanga, Lisa Lamprou, Claudia Schinstine, Mark Elliott, Hari Hariharan, Ravinder Reddy, C Neill Epperson.   

Abstract

Gamma-aminobutyric acid (GABA) and glutamate are implicated in numerous neuropsychiatric and substance abuse conditions, but their spectral overlap with other resonances makes them a challenge to quantify in humans. Gabapentin, marketed for the treatment of seizures and neuropathic pain, has been shown to increase in vivo GABA concentration in the brain of both rodents and humans. Gabapentin effects on glutamate are not known. We conducted a gabapentin (900 mg) challenge in healthy human subjects to confirm and explore its effects on GABA and glutamate concentrations, respectively, and to test the ability of single voxel localized proton magnetic resonance spectroscopy (¹H-MRS) to reliably measure GABA and glutamate in the visual cortex at the ultra-high magnetic field of 7 Tesla. Reproducibility of GABA and glutamate measurements was determined in a comparison group without drug twice within day and 2 weeks apart. Although GABA concentration changes were small both within day (average 5.6%) and between day (average 4.8%), gabapentin administration was associated with an average increase in GABA concentration of 55.7% (6.9-91.0%). Importantly, drug-induced change in GABA levels was inversely correlated to the individual's baseline GABA level (R²=0.72). Mean glutamate concentrations did not change significantly with or without drug administration. In conclusion, localized ¹H-MRS at 7 Tesla can be successfully applied to the measurement of GABA concentration and is sensitive to acute drug-induced changes in cortical GABA. Whether baseline GABA concentrations predict clinical efficacy of gabapentin is an area worthy of exploration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871916      PMCID: PMC3499716          DOI: 10.1038/npp.2012.142

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  59 in total

1.  Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.

Authors:  Lawrence S Kegeles; Xiangling Mao; Arielle D Stanford; Ragy Girgis; Najate Ojeil; Xiaoyan Xu; Roberto Gil; Mark Slifstein; Anissa Abi-Dargham; Sarah H Lisanby; Dikoma C Shungu
Journal:  Arch Gen Psychiatry       Date:  2012-01-02

2.  Efficacy of gabapentin in migraine prophylaxis.

Authors:  N T Mathew; A Rapoport; J Saper; L Magnus; J Klapper; N Ramadan; B Stacey; S Tepper
Journal:  Headache       Date:  2001-02       Impact factor: 5.887

3.  Quantitative proton short-echo-time LASER spectroscopy of normal human white matter and hippocampus at 4 Tesla incorporating macromolecule subtraction.

Authors:  Mohamed N E Kassem; Robert Bartha
Journal:  Magn Reson Med       Date:  2003-05       Impact factor: 4.668

4.  Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla.

Authors:  Rosane Gomez; Kevin L Behar; June Watzl; Stuart A Weinzimer; Barbara Gulanski; Gerard Sanacora; Julia Koretski; Elizabeth Guidone; Lihong Jiang; Ismene L Petrakis; Brian Pittman; John H Krystal; Graeme F Mason
Journal:  Biol Psychiatry       Date:  2011-08-19       Impact factor: 13.382

5.  Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients.

Authors:  O A Petroff; F Hyder; D L Rothman; R H Mattson
Journal:  Epilepsia       Date:  2000-06       Impact factor: 5.864

6.  Prefrontal cortical gamma-aminobutyric Acid levels in panic disorder determined by proton magnetic resonance spectroscopy.

Authors:  Gregor Hasler; Jan Willem van der Veen; Marilla Geraci; Jun Shen; Daniel Pine; Wayne C Drevets
Journal:  Biol Psychiatry       Date:  2008-08-09       Impact factor: 13.382

7.  Brain GABA editing by localized in vivo (1)H magnetic resonance spectroscopy.

Authors:  G Bielicki; C Chassain; J P Renou; M C Farges; M P Vasson; A Eschalier; F Durif
Journal:  NMR Biomed       Date:  2004-04       Impact factor: 4.044

8.  Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA.

Authors:  A Goldlust; T Z Su; D F Welty; C P Taylor; D L Oxender
Journal:  Epilepsy Res       Date:  1995-09       Impact factor: 3.045

9.  Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study.

Authors:  C Neill Epperson; Kristin Haga; Graeme F Mason; Edward Sellers; Ralitza Gueorguieva; Wenjiang Zhang; Erica Weiss; Douglas L Rothman; John H Krystal
Journal:  Arch Gen Psychiatry       Date:  2002-09

10.  Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens.

Authors:  Marcello Solinas; Sergi Ferré; Zhi-Bing You; Marzena Karcz-Kubicha; Patrizia Popoli; Steven R Goldberg
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

View more
  41 in total

1.  Effect of Primidone on Dentate Nucleus γ-Aminobutyric Acid Concentration in Patients With Essential Tremor.

Authors:  Elan D Louis; Nora Hernandez; Jonathan P Dyke; Ruoyun Ma; Ulrike Dydak
Journal:  Clin Neuropharmacol       Date:  2016 Jan-Feb       Impact factor: 1.592

Review 2.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Authors:  Michelle M Kim; Abhijit Parolia; Mark P Dunphy; Sriram Venneti
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

3.  Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Michael J Wesley; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

Review 4.  Misuse and abuse of pregabalin and gabapentin: cause for concern?

Authors:  Fabrizio Schifano
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

5.  Frontal Gamma-Aminobutyric Acid Concentrations Are Associated With Cognitive Performance in Older Adults.

Authors:  Eric C Porges; Adam J Woods; Richard A E Edden; Nicolaas A J Puts; Ashley D Harris; Huaihou Chen; Amanda M Garcia; Talia R Seider; Damon G Lamb; John B Williamson; Ronald A Cohen
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-01

6.  GABA metabolism and its role in gamma-band oscillatory activity during auditory processing: An MRS and EEG study.

Authors:  Christine Wyss; Desmond H Y Tse; Michael Kometer; Jürgen Dammers; Rita Achermann; N Jon Shah; Wolfram Kawohl; Irene Neuner
Journal:  Hum Brain Mapp       Date:  2017-05-08       Impact factor: 5.038

Review 7.  Neuroimaging of Pain: Human Evidence and Clinical Relevance of Central Nervous System Processes and Modulation.

Authors:  Katherine T Martucci; Sean C Mackey
Journal:  Anesthesiology       Date:  2018-06       Impact factor: 7.892

8.  Lisdexamfetamine Effects on Executive Activation and Neurochemistry in Menopausal Women with Executive Function Difficulties.

Authors:  Sheila Shanmugan; James Loughead; Ravi Prakash Reddy Nanga; Mark Elliott; Hari Hariharan; Dina Appleby; Deborah Kim; Kosha Ruparel; Ravinder Reddy; Thomas E Brown; C Neill Epperson
Journal:  Neuropsychopharmacology       Date:  2016-08-23       Impact factor: 7.853

9.  γ-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers.

Authors:  Andrew P Prescot; Perry F Renshaw; Deborah A Yurgelun-Todd
Journal:  Drug Alcohol Depend       Date:  2013-03-21       Impact factor: 4.492

10.  Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.

Authors:  Raymond F Anton; Patricia Latham; Konstantin Voronin; Sarah Book; Michaela Hoffman; James Prisciandaro; Emily Bristol
Journal:  JAMA Intern Med       Date:  2020-05-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.